WO2008136705A2 - Средство для лeчehия и профилактики доброкачественной гиперплазии предстательной железы простатита, импотенции, бесплодия и рака предстательной железы и способ его применения - Google Patents
Средство для лeчehия и профилактики доброкачественной гиперплазии предстательной железы простатита, импотенции, бесплодия и рака предстательной железы и способ его применения Download PDFInfo
- Publication number
- WO2008136705A2 WO2008136705A2 PCT/RU2008/000164 RU2008000164W WO2008136705A2 WO 2008136705 A2 WO2008136705 A2 WO 2008136705A2 RU 2008000164 W RU2008000164 W RU 2008000164W WO 2008136705 A2 WO2008136705 A2 WO 2008136705A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- camphor
- oil
- fat
- emulsion
- dimexide
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 229940079593 drug Drugs 0.000 title claims abstract description 32
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 30
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 16
- 208000000509 infertility Diseases 0.000 title claims abstract description 14
- 230000036512 infertility Effects 0.000 title claims abstract description 14
- 231100000535 infertility Toxicity 0.000 title claims abstract description 14
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 9
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 9
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 145
- 229960000846 camphor Drugs 0.000 claims abstract description 141
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 135
- 229930008380 camphor Natural products 0.000 claims abstract description 134
- 238000011282 treatment Methods 0.000 claims abstract description 71
- 239000000839 emulsion Substances 0.000 claims abstract description 65
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000000829 suppository Substances 0.000 claims abstract description 7
- 235000019486 Sunflower oil Nutrition 0.000 claims description 41
- 239000002600 sunflower oil Substances 0.000 claims description 41
- 239000010642 eucalyptus oil Substances 0.000 claims description 34
- 239000010645 fir oil Substances 0.000 claims description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 30
- 235000015277 pork Nutrition 0.000 claims description 26
- 239000006215 rectal suppository Substances 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 21
- 229940044949 eucalyptus oil Drugs 0.000 claims description 17
- 201000001881 impotence Diseases 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 208000013507 chronic prostatitis Diseases 0.000 claims description 14
- 239000002569 water oil cream Substances 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 12
- 229930007886 (R)-camphor Natural products 0.000 claims description 6
- 229940100618 rectal suppository Drugs 0.000 claims description 6
- 230000005713 exacerbation Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 239000000084 colloidal system Substances 0.000 abstract description 5
- 206010021143 Hypoxia Diseases 0.000 abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000003480 fibrinolytic effect Effects 0.000 abstract description 3
- 230000007954 hypoxia Effects 0.000 abstract description 3
- 235000021317 phosphate Nutrition 0.000 abstract description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000001457 vasomotor Effects 0.000 abstract description 3
- 210000000264 venule Anatomy 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 210000001002 parasympathetic nervous system Anatomy 0.000 abstract description 2
- 239000002574 poison Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000001256 tonic effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 description 28
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 238000011321 prophylaxis Methods 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- -1 Omnodren Chemical compound 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 229940030486 androgens Drugs 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 241000606540 Chione venosa Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940117229 cialis Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229940097443 levitra Drugs 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000032630 lymph circulation Effects 0.000 description 2
- 235000021184 main course Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010069918 Bacterial prostatitis Diseases 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 240000008243 Corypha umbraculifera Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 208000034793 Feminization Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000235624 Ocimum kilimandscharicum Species 0.000 description 1
- 235000006600 Ocimum kilimandscharicum Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920000081 Polyestradiol phosphate Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038967 Retrograde ejaculation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010049679 Spinal shock Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000008931 Tadenan Substances 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229940072282 cardura Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 229960003839 dienestrol Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940014903 tadenan Drugs 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the pharmaceutical industry and medicine.
- BPH benign prostatic hyperplasia
- prostatitis a prostatic hyperplasia
- impotence a prostatic hyperplasia
- infertility prostate cancer
- androgens Sustanon, Omnodren, Methyltestosterone, Testobromlecitis, Testosterone Propionate.
- Observations showed that androgens do not reduce and do not delay the further growth of growth adenomas (l).
- estrogens were prescribed: synestrol, estradurin.
- synestrol estradurin.
- the introduction of female sex hormones leads to the reverse development of not the adenoma, but the glandular elements of the prostate's own tissue (2).
- Ll-blockers cause orthostatic reactions, dizziness, headache, fatigue, malaise, swelling, asthenia, drowsiness, nausea, rhinitis, retrograde ejaculation.
- 5-L-reductase blockers impotence, decreased libido, decreased ejaculate volume.
- drugs of various groups are used: antibiotics, sulfanilamides, androgens, enzymes, herbal preparations, physiotherapeutic treatment, physiotherapy exercises, and spa treatment.
- Phosphodiesterase inhibitors (Viagra, Cialis, Levitra) are used to treat erectile dysfunction. A special place is occupied by the method of intracavernous administration of vasoactive drugs (coverjack, papaverine). Long
- Viagra, Cialis, Levitra have many contraindications and side effects: asthenia, abdominal pain, back pain, diarrhea, nausea, muscle and joint pain, fainting, insomnia, pharyngitis, rhinitis, respiratory failure, changes in vision, impaired prostate function glands, palpitations, tachycardia, vomiting, etc.
- the most significant side effects when using drugs such as coverject are psychoses, convulsions, bleeding, priapism. And at present, there is no experience with the use of these drugs in patients under the age of 18 and older than 75 years. Methods of surgical treatment and prosthetics are non-physiological.
- the objective of the invention was to develop a tool for the treatment and prevention of BPH, prostatitis, impotence, infertility and prostate cancer, using camphor preparations that can significantly and quickly reduce the volume of the prostate gland, weaken the dynamic component of obstruction, effective in the treatment of prostatitis, infertility, impotence.
- camphor preparations (dextrorotatory [D-], levorotatory [L], racemic [DL-camphor], as well as their different composition) mainly in the form of a fat-oil-dimexide emulsion (Em. Samhorah Ahshigio - Oleo-Dimehidosa ), an oil-water emulsion (Emulsio Samphora oleo-Agvosa), in the form of suppositories and rectal administration of these drugs.
- D- fat-oil-dimexide emulsion
- Emulsio Samphora oleo-Agvosa oil-water emulsion
- h SUBSTITUTE SHEET (RULE 26) hydrophilic properties of biocolloids of the prostate gland and the associated restoration of lymph and blood circulation (by the mechanism of colloid protection).
- camphor is characterized by a minimum amount of dry matter, preventing from coagulation (the so-called golden number) in a dose of 0.1-15.0.
- An agent for the treatment and prevention of benign prostatic hyperplasia, prostatitis, impotence, infertility and prostate cancer, including camphor characterized in that it is made in the form of a fat-oil-dimexide emulsion Em. Samhora Ahupgio-Oleo-Dimechidosa, or Em oil-in-water emulsion. Samhore Oleo-Aguosa, or in the form of candles Surr. Samphora, while containing components, vol%:
- the tool characterized in that the fat-oil-dimexidic emulsion camphor-dextrorotatory [D] has the following ratio of components, about.%:
- the tool characterized in that the fat-oil-dimexidic emulsion of camphor - levorotatory [L] has the following ratio of components, vol%:
- the tool characterized in that the fat-oil-dimexidic emulsion of camphor-racemic [DL] has the following ratio of components, vol.%:
- the tool characterized in that the fat-oil-dimexide emulsion of camphor, while the proportion of dextrorotatory D-camphor can be from 0.1% to 99.9%, the proportion of levorotatory L-camphor can be from 0.1% to 99.9 %, has the following ratio of components, vol.%:
- the tool characterized in that the oil-water emulsion of camphor-converting [D] has the following ratio of components, vol.%:
- the tool characterized in that the oil-water emulsion of camphor - levorotatory [L] has the following ratio of components, vol.%:
- the tool characterized in that the oil-water emulsion of camphor-racemic [DL] has the following ratio of components, vol.%:
- the tool characterized in that the oil-water emulsion of camphor (the proportion of dextrorotatory D-camphor can be from 0.1 to 99.9%, the proportion of levorotatory L-camphor can be from 0.1 to 99.9%) has the following ratio of components. vol.%:
- the tool characterized in that the rectal suppository containing levorotatory - [L] camphor, have the following ratio of components necessary for the preparation of one suppository in the city:
- the tool characterized in that the rectal suppository containing racemic - [DL] camphor, have the following ratio of components necessary for the preparation of one candle in the city:
- the tool characterized in that the rectal suppositories, where the proportion of dextrorotatory camphor-D can be from 0.1% to 99, 9%, the proportion of levorotatory - [L] camphor can be from 0.1% to 99.9%, have the following the ratio of components necessary for the preparation of one candle in the city:
- An agent for the treatment and prevention of benign prostatic hyperplasia, prostatitis, impotence, infertility and prostate cancer including camphor, characterized in that fir-oil and eucalyptus oil are introduced into the fat-oil-dimexidic emulsion of camphor, and it has the following ratio of components, ob. %:
- the tool characterized in that the fat-oil-dimexide emulsion camphor-dextrorotatory [D] with the addition of fir and eucalyptus oils has the following ratio of components, about.%:
- the tool characterized in that the fat-oil-dimexidic emulsion of camphor-levorotatory [L] with the addition of fir and eucalyptus oils has the following ratio of components, vol.%:
- the agent characterized in that the fat-oil-dimexide emulsion of camphor-racemic [DL] with the addition of fir and eucalyptus oils has the following ratio of components. vol.%:
- the tool characterized in that the fat-oil-dimexide emulsion of camphor, while the proportion of dextrorotatory D-camphor can be from 0.1% to 99.9%, the proportion of levorotatory L-camphor can be from 0.1% to 99.9 %, with the addition of fir and eucalyptus oils has the following ratio of components about.%:
- a method of using the agent characterized in that for the treatment and prevention of chronic prostatitis or prostate cancer, a fat-oil-dimexide emulsion of camphor and rectal suppositories are used.
- the method of application of the drug characterized in that for the treatment and prevention of BPH use fat - oil - dimexide emulsion of camphor and rectal suppository.
- a method of using the agent characterized in that for the treatment and prevention of impotence or infertility, a camphor fat-oil-dimexide emulsion is used.
- a method of using the product characterized in that for the treatment and prevention of acute prostatitis or exacerbation of chronic prostatitis, camphor oil-oil-dimexide emulsion, camphor oil-oil-dimexide emulsion with the addition of fir and eucalyptus oils, camphor oil-water emulsion and rectal suppositories are used.
- the water is distilled the rest.
- Rectal suppositories (amount of camphor, and fat base per candle in a year)
- the method of application of the claimed drug is characterized in that for the treatment and prevention of chronic prostatitis or prostate cancer, fat-oil-dimexide emulsion of camphor and rectal suppository are used; For the treatment and prevention of BPH, a camphor fat-oil-dimexide emulsion and rectal suppositories are used; for the treatment and prevention of impotence or infertility, a camphor fat-oil-dimexide emulsion is used; for the treatment and prevention of acute prostatitis or exacerbation of chronic prostatitis, camphor fat-oil-dimexide emulsion, camphor fat-oil-dimexide emulsion with the addition of fir and eucalyptus oils, camphor oil-water emulsion and rectal suppositories are used; the drug is administered rectally.
- BPH patients used 0.1% rectal suppositories with camphor.
- the number of patients is 122 people.
- the quality of life of L patients has not changed.
- the protective effect of the lyophilic camphor colloid is manifested in relation to the biocolloids of the main substance of stromal tissue and the secretion of the prostate gland, which, due to the changes (in the elderly and senile, with inflammation), acquire hydrophobic properties, which is accompanied by the effects of colloidoclasia.
- the very nature of blood flow and lymph circulation in the prostate gland changes, which leads to a known violation
- Camphor affects the metabolism of macroergic phosphorus compounds, ATP cleavage during hypoxia is inhibited, which is explained by increased oxidative resynthesis of macroergic phosphates due to activation of anaerobic glycolysis (8). It is considered proven that if the content of AMP acid decreases, then the sperm lose their mobility. The stimulating effect of camphor on the vasomotor centers of the spinal cord is proved. Camphor can change vascular tone, acting on vascular chemoreceptors. Camphor normalizes the tone of capillaries and venules and restores the disturbed permeability of capillary membranes. Camphor is a reliable remedy that tones venous vessels (8).
- camphor causes an increase in the reflex activity of the spinal centers of the lumbar or resumes it in cases of spinal shock, which can be interpreted as a result of the direct effect of camphor on the spinal centers (9).
- One of the essential properties that determine the pharmacodynamics of camphor is its M - and H - anticholinergic action. When it enters the blood and lymph, it is sorbed on red blood cells, lipoprotein complexes, proteins, foreign particles-microbes, fibrin flakes, which contributes to their elimination.
- the raw material for camphor is camphor laurel (Sipamomum Samhora), which grows wild in China and Japan, as well as camphor basil (Osmum Sapup Sims.), which grows in Africa and southern China.
- Fir oil contains more than 35 biologically active substances. So phytoncides have a detrimental effect on microbes. Activates the function of the gonads, as contains vitamin E from 0.6% to 1.6%, easily penetrates the skin and mucous membranes. Dimexide also has the ability to penetrate through biological membranes, thus realizing its specific effects, which include: anti-inflammatory, antipyretic, antiseptic,
- eucalyptus oil mainly consists in antimicrobial anti-inflammatory effects. Received medicines are applied rectally once a day.
- the indication for the treatment of BPH patients was the presence of clinical manifestations of complaints (according to the J-PSS scale, this amounted to 20 or more points).
- the fat-oil-dimexide emulsion was mainly used by introducing it into the anus in an amount of 5 ml using microclysters once a day for 2-4 months until the clinical manifestations were stabilized. Patients were examined before treatment and after 2-4 months.
- the following indicators were used to evaluate the results of treatment: -clinical manifestations according to the J-PSS scale; - indicators of quality of life; uroflowmetric index; - prostate volume; - the amount of residual urine in patients 2 tbsp.
- camphor fat-oil-dimexidic emulsion was used continuously from 2 to 6 months, 5 ml each. once a day at night.
- Camphor preparations the effectiveness of which has been proven with rectal administration, have the following pharmacological properties:
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112008001179T DE112008001179T5 (de) | 2007-05-03 | 2008-03-14 | Mittel für die Behandlung und zur Vorsorge von gutartiger Prostatahyperplasie, Prostatitis, Impotenz, Unfruchtbarkeit und Prostatakarzinom und das Verfahren seiner Anwendung |
JP2010507349A JP2010526137A (ja) | 2007-05-03 | 2008-03-14 | 良性前立腺肥大症、前立腺炎、不能症、不妊症および前立腺癌の治療および予防のための薬剤、およびそれらの使用方法 |
US12/450,595 US20100112102A1 (en) | 2007-05-03 | 2008-03-14 | Therapeutic compositions for the treatment of benigh prostate hyperplasia, prostatitis, impotence, infertility and prostate cancer and a method for the use thereof |
CN200880014576A CN101678062A (zh) | 2007-05-03 | 2008-03-14 | 用于治疗和预防良性前列腺增生、前列腺炎、阳痿、不育和前列腺癌的药物及其应用方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2007117858/15A RU2336894C1 (ru) | 2007-05-03 | 2007-05-03 | Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и рака предстательной железы и способ его применения |
RU2007117858 | 2007-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008136705A2 true WO2008136705A2 (ru) | 2008-11-13 |
WO2008136705A3 WO2008136705A3 (ru) | 2008-12-31 |
Family
ID=39944131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2008/000164 WO2008136705A2 (ru) | 2007-05-03 | 2008-03-14 | Средство для лeчehия и профилактики доброкачественной гиперплазии предстательной железы простатита, импотенции, бесплодия и рака предстательной железы и способ его применения |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100112102A1 (ru) |
JP (1) | JP2010526137A (ru) |
CN (1) | CN101678062A (ru) |
DE (1) | DE112008001179T5 (ru) |
RU (1) | RU2336894C1 (ru) |
UA (1) | UA56965U (ru) |
WO (1) | WO2008136705A2 (ru) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2538615C1 (ru) * | 2013-08-20 | 2015-01-10 | Общество с ограниченной ответственностью "УНИФАРМ" (ООО "УНИФАРМ"). | Средство для профилактики и лечения простатита и аденомы предстательной железы |
CN104306585A (zh) * | 2014-11-04 | 2015-01-28 | 王松华 | 一种用于治疗前列腺炎的中药组合物及其制备方法与应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101253282B1 (ko) * | 2011-04-22 | 2013-04-10 | 한국과학기술연구원 | 피톤치드 방출 스텐트 |
RU2532353C1 (ru) * | 2013-04-25 | 2014-11-10 | Федеральное государственное бюджетное учреждение "Пятигорский государственный научно-исследовательский институт курортологии Федерального медико-биологического агентства" (ФГБУ ПГНИИК ФМБА России) | Способ лечения доброкачественной гиперплазии предстательной железы, осложненной хроническим простатитом с доминирующим симптомом ноктурии на курорте |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2067441C1 (ru) * | 1991-12-26 | 1996-10-10 | Мехраб Магомед оглы Салманов | Способ лечения больных хроническим неспецифическим простатитом |
RU2140265C1 (ru) * | 1998-10-27 | 1999-10-27 | Чернобаев Николай Евгеньевич | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы |
KR20010089975A (ko) * | 2000-04-07 | 2001-10-17 | 안종훈 | 캡사이신을 이용한 만성 전립선염, 전립선 비대증, 치질및 발기부전 치료제 |
RU2236218C1 (ru) * | 2003-04-29 | 2004-09-20 | Российский научный центр восстановительной медицины и курортологии | Способ лечения больных хроническим простатитом |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US273552A (en) * | 1883-03-06 | Territory | ||
JP3420540B2 (ja) * | 1999-01-29 | 2003-06-23 | 天藤製薬株式会社 | 坐剤用基剤及び坐剤 |
JP4438908B2 (ja) * | 1999-03-19 | 2010-03-24 | 千寿製薬株式会社 | テルペノイドエマルション |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
WO2004084877A1 (ja) * | 2003-03-26 | 2004-10-07 | Menicon Co., Ltd. | 眼科用組成物 |
US20070053861A1 (en) * | 2003-09-10 | 2007-03-08 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition for contact lens |
-
2007
- 2007-05-03 RU RU2007117858/15A patent/RU2336894C1/ru not_active IP Right Cessation
-
2008
- 2008-03-14 JP JP2010507349A patent/JP2010526137A/ja active Pending
- 2008-03-14 US US12/450,595 patent/US20100112102A1/en not_active Abandoned
- 2008-03-14 CN CN200880014576A patent/CN101678062A/zh active Pending
- 2008-03-14 WO PCT/RU2008/000164 patent/WO2008136705A2/ru active Application Filing
- 2008-03-14 DE DE112008001179T patent/DE112008001179T5/de not_active Ceased
- 2008-03-14 UA UAA200909715U patent/UA56965U/ru unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2067441C1 (ru) * | 1991-12-26 | 1996-10-10 | Мехраб Магомед оглы Салманов | Способ лечения больных хроническим неспецифическим простатитом |
RU2140265C1 (ru) * | 1998-10-27 | 1999-10-27 | Чернобаев Николай Евгеньевич | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы |
KR20010089975A (ko) * | 2000-04-07 | 2001-10-17 | 안종훈 | 캡사이신을 이용한 만성 전립선염, 전립선 비대증, 치질및 발기부전 치료제 |
RU2236218C1 (ru) * | 2003-04-29 | 2004-09-20 | Российский научный центр восстановительной медицины и курортологии | Способ лечения больных хроническим простатитом |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2538615C1 (ru) * | 2013-08-20 | 2015-01-10 | Общество с ограниченной ответственностью "УНИФАРМ" (ООО "УНИФАРМ"). | Средство для профилактики и лечения простатита и аденомы предстательной железы |
CN104306585A (zh) * | 2014-11-04 | 2015-01-28 | 王松华 | 一种用于治疗前列腺炎的中药组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
DE112008001179T5 (de) | 2010-06-02 |
JP2010526137A (ja) | 2010-07-29 |
UA56965U (ru) | 2011-02-10 |
WO2008136705A3 (ru) | 2008-12-31 |
CN101678062A (zh) | 2010-03-24 |
US20100112102A1 (en) | 2010-05-06 |
RU2336894C1 (ru) | 2008-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2292402T3 (es) | Composicion de donador de oxido nitrico y metodo para el tratamiento de afecciones anales. | |
Ralph et al. | Ejaculatory disorders and sexual function. | |
WO2008136705A2 (ru) | Средство для лeчehия и профилактики доброкачественной гиперплазии предстательной железы простатита, импотенции, бесплодия и рака предстательной железы и способ его применения | |
VM et al. | Female infertility and its treatment by alternative medicine: a review | |
McMahon et al. | Ejaculatory disorders | |
RU2709958C1 (ru) | Способ лечения эректильной дисфункции | |
Wójcik et al. | APPLICATION PHYSIOTHERAPY AND BALNEOCLIMATOLOGY IN GYNAECOLOGY. | |
RU2730483C1 (ru) | Способ приготовления фармацевтической гелевой композиции для лечения проктологических заболеваний (варианты). | |
Riisfeldt | Methods and results in 117 cases of amenorrhea treated with gonadotropic hormones | |
ASMAA et al. | Effect of pulsed electromagnetic field versus aerobic exercise on primary dysmenorrhea | |
CN101940652B (zh) | 治疗牛皮癣、各种顽癣、瘙痒症的中药擦剂 | |
RU2236218C1 (ru) | Способ лечения больных хроническим простатитом | |
RU2140265C1 (ru) | Средство для лечения и профилактики доброкачественной гиперплазии простаты (дгп), простатита, импотенции, бесплодия и рака предстательной железы | |
RU2817847C1 (ru) | Суппозиторий для лечения ректальных трещин гиалуроновый с димексидом | |
RU2785754C1 (ru) | Способ прегравидарной подготовки женщин с нарушениями репродуктивной функции на санаторно-курортном этапе | |
RU2819077C1 (ru) | Способ лечения мастопатии | |
Reddy et al. | MANAGEMENT OF DADRU WITH DADRUHARA LEPA AND GANDHAK RASAYANA: A CASE STUDY | |
Abd-Elmaged et al. | Effects of Warm Water Sitz Bath on Post-Hemorrhoidectomy Symptoms | |
Feruzabonu et al. | Natural methods of achieving safe motherhood | |
Capodice | Acupuncture | |
Mahajan et al. | Chapter-5 Shiroabhitapa: A Persisting Ailment | |
JPS61207336A (ja) | 鎮痛消炎剤 | |
Tella et al. | Effects of Transcutaneous Electrical Nerve Stimulation (TENS) On Hormone profiles In Subjects With Primary Dysmenorrhoea-A Preliminary Study | |
RU2529812C2 (ru) | Биологически активная композиция | |
Migliorini et al. | HP-3-2 Percutaneous Angioplasty of Internal Pudendal Arteries for the Treatment of Arteriogenic Erectile Dysfunction. Initial Experience in Six Patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880014576.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08753874 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 12450595 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010507349 Country of ref document: JP Ref document number: 1120080011796 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08753874 Country of ref document: EP Kind code of ref document: A2 |
|
RET | De translation (de og part 6b) |
Ref document number: 112008001179 Country of ref document: DE Date of ref document: 20100602 Kind code of ref document: P |